CO6640239A2 - Proceso par preparar una composición de inmunoglobulina - Google Patents

Proceso par preparar una composición de inmunoglobulina

Info

Publication number
CO6640239A2
CO6640239A2 CO12211856A CO12211856A CO6640239A2 CO 6640239 A2 CO6640239 A2 CO 6640239A2 CO 12211856 A CO12211856 A CO 12211856A CO 12211856 A CO12211856 A CO 12211856A CO 6640239 A2 CO6640239 A2 CO 6640239A2
Authority
CO
Colombia
Prior art keywords
solution
immunoglobulins
lgm
preparation
immunoglobulin
Prior art date
Application number
CO12211856A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Moller
Dieter Rudnick
Oliver Maneg
Michael Rodemer
Herbert Dichtelmuller
Eckhard Flechsig
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42270688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6640239(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CO6640239A2 publication Critical patent/CO6640239A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO12211856A 2010-04-22 2012-11-22 Proceso par preparar una composición de inmunoglobulina CO6640239A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition

Publications (1)

Publication Number Publication Date
CO6640239A2 true CO6640239A2 (es) 2013-03-22

Family

ID=42270688

Family Applications (2)

Application Number Title Priority Date Filing Date
CO12211856A CO6640239A2 (es) 2010-04-22 2012-11-22 Proceso par preparar una composición de inmunoglobulina
CO12211854A CO6640238A2 (es) 2010-04-22 2012-11-22 Preparaciones de anticuerpos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO12211854A CO6640238A2 (es) 2010-04-22 2012-11-22 Preparaciones de anticuerpos

Country Status (18)

Country Link
US (6) US9243056B2 (enExample)
EP (2) EP2560691B1 (enExample)
JP (4) JP6283517B2 (enExample)
KR (2) KR101872747B1 (enExample)
CN (3) CN107080842A (enExample)
AU (2) AU2011244241B2 (enExample)
CA (2) CA2796409A1 (enExample)
CO (2) CO6640239A2 (enExample)
ES (2) ES2553385T3 (enExample)
GB (1) GB201006753D0 (enExample)
HU (2) HUE028581T2 (enExample)
IL (2) IL222374A (enExample)
MX (2) MX337060B (enExample)
PL (2) PL2560682T5 (enExample)
RU (4) RU2765738C2 (enExample)
SG (2) SG184844A1 (enExample)
WO (2) WO2011131786A2 (enExample)
ZA (2) ZA201208541B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
KR20150115639A (ko) * 2014-04-04 2015-10-14 전숙영 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제
WO2016011054A2 (en) * 2014-07-15 2016-01-21 The Regents Of The University Of California Novel treatment for polycystic kidney disease
EP3334747B1 (en) 2015-08-13 2023-09-27 Amgen Inc. Charged depth filtration of antigen-binding proteins
ES2881201T3 (es) 2016-03-14 2021-11-29 Biotest Ag Tratamiento de la neumonía grave adquirida en la comunidad
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
RU2660584C1 (ru) * 2017-06-06 2018-07-06 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ определения FC-функции препаратов иммуноглобулина человека
PL3717916T3 (pl) * 2017-11-29 2025-04-07 F. Hoffmann-La Roche Ag Test do oznaczania przeciwciał przeciwlekowych z tłumieniem oddziaływania z cząsteczką docelową
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CN115697395A (zh) * 2020-04-10 2023-02-03 瓦努迪斯有限公司 预防和治疗中的天然抗体
CN115697408A (zh) * 2020-06-03 2023-02-03 基立福环球运营有限公司 超免疫igg和/或igm组合物及其制备方法及自捐献者获得超免疫人血浆的方法
TW202216735A (zh) * 2020-07-10 2022-05-01 愛爾蘭商格里佛全球營運有限公司 製備包含人血漿來源的免疫球蛋白ｍ之組合物的方法及儲存穩定的液體組合物
CN111944043B (zh) * 2020-09-01 2023-05-09 华兰生物工程重庆有限公司 一种从血浆废弃物中提取IgM的方法
EP4193155A1 (en) 2020-11-19 2023-06-14 Biotest AG Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
EP4377361A1 (en) 2021-07-29 2024-06-05 CSL Behring AG Method of purifying immunoglobulin g and uses thereof
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions
WO2025008781A1 (en) 2023-07-04 2025-01-09 Csl Behring Ag Method of purification
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136556A (en) 1873-03-04 Improvements in button-fastenings
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
US4371520A (en) * 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
IL90281A (en) 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927112C1 (enExample) 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
DE29624488U1 (de) 1995-07-14 2004-04-15 Croix-Rouge De Belgique Anlage zur Inaktivierung von in Blutprodukten enthaltenen Kontaminierungen
EP0764658B1 (de) 1995-09-22 2002-01-02 ZLB Bioplasma AG Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JP3987599B2 (ja) * 1996-12-05 2007-10-10 日本製薬株式会社 筋ジストロフィー治療剤
JPH10167894A (ja) * 1996-12-11 1998-06-23 Mitsubishi Gas Chem Co Inc ビスマス置換希土類鉄ガーネット単結晶膜の製造法
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
PL196770B1 (pl) 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
RU2178309C2 (ru) * 2000-01-12 2002-01-20 Российский научно-исследовательский институт геронтологии Антитимоцитарный глобулин для внутривенного введения и способ его получения
RU2192279C2 (ru) * 2000-09-07 2002-11-10 Нижегородское государственное предприятие по производству бактерийных препаратов Способ получения иммуноглобулинового препарата
AU2002229545B2 (en) 2000-11-13 2007-08-30 Bayer Aktiengesellschaft Method of inactivating microorganisms in a fluid using ultraviolet radiation
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003037504A1 (en) 2001-11-02 2003-05-08 Japan Techno Co., Ltd. Vibratory stirrer for sterilization and sterilizer and sterilization method employing vibratory stirrer
RU2255766C2 (ru) * 2003-03-05 2005-07-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата
US8980646B2 (en) 2003-03-26 2015-03-17 Sudhir Paul Proteolytic and covalent antibodies
AU2004286938B2 (en) 2003-10-27 2011-06-30 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
PL1718675T3 (pl) 2004-02-27 2013-09-30 Octapharma Ag Sposób uzyskiwania oczyszczonego preparatu przeciwciał pozbawionego wirusów
ES2348792T3 (es) 2004-12-10 2010-12-14 Novimmune Sa TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
KR101157174B1 (ko) 2005-11-24 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 신속한 파괴 방법 및 장치
DE102005062634A1 (de) 2005-12-23 2007-06-28 Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung
FR2899112B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
US8354076B2 (en) 2006-10-02 2013-01-15 Palo Alto Research Center Incorporated Fluid stirring mechanism
EP1950225A1 (de) 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
RU2457863C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
RU2457861C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
NZ591514A (en) 2011-03-03 2013-11-29 Kode Biotech Ltd Assay method

Also Published As

Publication number Publication date
MX338195B (es) 2016-04-06
AU2011244240B2 (en) 2014-12-04
KR101872747B1 (ko) 2018-06-29
BR112012026934A2 (pt) 2015-09-22
IL222374A0 (en) 2012-12-31
IL222374A (en) 2017-04-30
WO2011131786A2 (en) 2011-10-27
KR20130094718A (ko) 2013-08-26
ES2551605T5 (es) 2024-06-27
ES2551605T3 (es) 2015-11-20
AU2011244241B2 (en) 2014-12-04
RU2016140455A3 (enExample) 2020-04-02
JP6612186B2 (ja) 2019-11-27
ZA201208541B (en) 2015-06-24
CA2796263A1 (en) 2011-10-27
PL2560682T3 (pl) 2016-04-29
RU2016140455A (ru) 2018-12-17
US20150064170A1 (en) 2015-03-05
US10954290B2 (en) 2021-03-23
RU2012149741A (ru) 2014-05-27
BR112012026937A2 (pt) 2016-07-12
RU2749732C2 (ru) 2021-06-16
JP2016222674A (ja) 2016-12-28
US20170058020A1 (en) 2017-03-02
MX2012012262A (es) 2012-11-23
WO2011131787A3 (en) 2011-12-22
JP2016196477A (ja) 2016-11-24
US8900806B2 (en) 2014-12-02
US9518110B2 (en) 2016-12-13
IL222373A (en) 2016-02-29
KR101860459B1 (ko) 2018-05-23
PL2560691T3 (pl) 2016-04-29
CO6640238A2 (es) 2013-03-22
HK1180601A1 (zh) 2013-10-25
US20180319871A1 (en) 2018-11-08
CN102939111B (zh) 2014-10-29
CN107080842A (zh) 2017-08-22
SG184843A1 (en) 2012-11-29
PL2560682T5 (pl) 2024-04-29
EP2560682B1 (en) 2015-10-21
IL222373A0 (en) 2012-12-31
HK1177600A1 (zh) 2013-08-23
EP2560682B2 (en) 2024-01-17
CA2796409A1 (en) 2011-10-27
US20210179694A1 (en) 2021-06-17
EP2560691B1 (en) 2015-11-04
JP6612182B2 (ja) 2019-11-27
JP2013531630A (ja) 2013-08-08
EP2560682A2 (en) 2013-02-27
AU2011244240A1 (en) 2012-12-06
JP6283517B2 (ja) 2018-02-21
CA2796263C (en) 2019-05-14
RU2017111820A (ru) 2019-01-24
US20130045199A1 (en) 2013-02-21
RU2012149743A (ru) 2014-05-27
CN102939107A (zh) 2013-02-20
MX2012012263A (es) 2012-11-23
US20130052208A1 (en) 2013-02-28
MX337060B (es) 2016-02-09
KR20130060199A (ko) 2013-06-07
WO2011131786A3 (en) 2011-12-22
ES2553385T3 (es) 2015-12-09
AU2011244241A1 (en) 2012-12-06
US9243056B2 (en) 2016-01-26
US10059759B2 (en) 2018-08-28
CN102939111A (zh) 2013-02-20
RU2617532C2 (ru) 2017-04-25
JP2013530950A (ja) 2013-08-01
RU2017111820A3 (enExample) 2020-07-20
HUE028581T2 (en) 2016-12-28
GB201006753D0 (en) 2010-06-09
CN102939107B (zh) 2016-12-21
ZA201208540B (en) 2015-06-24
RU2765738C2 (ru) 2022-02-02
SG184844A1 (en) 2012-11-29
WO2011131787A2 (en) 2011-10-27
RU2612899C2 (ru) 2017-03-13
EP2560691A2 (en) 2013-02-27
HUE025853T2 (en) 2016-05-30
US11780909B2 (en) 2023-10-10
JP6118248B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
CO6640239A2 (es) Proceso par preparar una composición de inmunoglobulina
Loomis et al. Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
Huang et al. Antibody recognition of the Pneumovirus fusion protein trimer interface
BR112015022790A8 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
CO6341572A2 (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
EP2581113A4 (en) ANTI-TIM-3 ANTIBODY
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
RU2014147741A (ru) Модифицированные области антител и их применение
RU2014140744A (ru) Композиции, содержащие секреторноподобные иммуноглобулины
HRP20220088T1 (hr) Dvojno-specifično fixaxfx antitijelo sa zajedničkim lakim lancem
MX2024007432A (es) Virus oncoliticos y metodo
Shinnakasu et al. Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
RU2698906C2 (ru) Способы и композиции для терапевтических агентов
BR112021024897A2 (pt) Métodos de produção de um anticorpo anti-a4ss7
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
Cunha et al. Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers
MX2023009447A (es) Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
HRP20220197T1 (hr) Antitijela protiv il-22r